Healthcare Industry News: SeptiCyte
News Release - October 22, 2015
Immunexpress Appoints Dr. Roy Davis Chief Medical OfficerSEATTLE, Oct. 22, 2015 -- (Healthcare Sales & Marketing Network) -- Immunexpress, Inc., a molecular diagnostic company committed to improving outcomes for suspected sepsis patients, today announced the appointment of Roy F. J. Davis, Ph.D., M.D., M.H.A., as Chief Medical Officer.
Dr. Davis previously served from 2002 through 2013 as Chief Medical Officer of Providence Health and Services' Alaska region where he assisted in the implementation of the modified early warning system (MEWS) and sepsis surveillance algorithms using the Microsoft Amalga platform. Dr. Davis was named the Microsoft Investigator of the Year for his work with MEWS in 2012. From 1986 to 1998, he was a Clinical Assistant Professor with the WAMI program in the Department of Pediatrics at the University of Washington.
Dr. Davis holds a medical degree and a Ph.D.in clinical chemistry from the Medical College of Virginia and completed his internship and residency in pediatrics at the University of Washington Children's Hospital. Dr. Davis also holds an M.H.A. from the University of Colorado School of Business.
Immunexpress is a Seattle-based molecular diagnostic company committed to improving outcomes for patients with, or at risk of, sepsis. Immunexpress's SeptiCyte® technology quantifies directly from whole blood specific molecular markers from the patient's own immune system – the "host response." Detecting the host's septic immune response can diagnose sepsis earlier and more accurately than current sepsis diagnostics that focus on identifying the invading pathogen. Immunexpress's pipeline includes monitoring assays for readily available platforms, including point-of-care (POC) sample-to-answer platforms. For more information visit www.Immunexpress.com.
Follow Immunexpress on Twitter at twitter.com/Immunexpress and LinkedIn at www.linkedin.com/company/immunexpress-inc.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.